Skip to main content
Jerrold Rosenbaum, MD, Psychiatry, Boston, MA, Massachusetts General Hospital

JerroldFrankRosenbaumMD

Psychiatry • Boston, MA

Psychiatrist-in-chief emeritus at the Massachusetts General Hospital and Stanley Cobb Professor of Psychiatry at Harvard Medical School

Join to view full profile

Dr. Rosenbaum is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rosenbaum's full profile

Already have an account?

Summary

  • Chief of Psychiatry, MGH; Stanley Cobb Professor of Psychiatry, Harvard Medical School
    Massachusetts General Hospital
    2002 – Present
    Dr. Rosenbaum directs a department of over 600 clinicians and researchers, and 150 trainees, ranked by U.S. News and World Report as the #1 Department of Psychiatry in the United States in 2016 and for 19 of the last 25 years, with 60 specialty clinical and research programs and over 60 million dollars of annual research spending. At MGH, the nation's largest hospital based research institution, with over 900 million dollars of annual research funding, he served as Chair of the Executive Committee on Research. He specializes in mood and anxiety disorders.
    He was the 2007 recipient of the C. Charles Burlingame Award given annually for lifetime achievement in psychiatric research and education by the Institute of Living, the 2011 Massachusetts Association of Mental Health Friend and Leader Awardee, and Psychiatrist of the Year for Research from the Massachusetts Psychiatric Society. He is the 2016 recipient of the Joseph B. Martin Dean's Leadership Award for the Advancement of Women Faculty for Harvard Medical School and Harvard School of Dental Medicine and 2018 Ellis Island Medal of Honor awardee.
    He served as President and the Chairman of the Board of the Anxiety and Depression Association of America (ADAA), is Chair of the Scientific Council and President of the Board of the American Foundation for Suicide Prevention and a Fellow emeritus of the American College of Neuropsychopharmacology. He served on the Board of Trustees of the Massachusetts General Hospital and on the Board of Trustees of the Partners Healthcare System and is co-Chair of Development at MGH. He directs the Center for Anxiety and Traumatic Stress Disorders at MGH.
    He is a co-founder of Psy Therapeutics, to advance the discovery of novel drugs and diagnostics for psychiatric and related disorders.

Education & Training

  • Massachusetts General Hospital/McLean Hospital
    Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1974 - 1977
  • Yale School of Medicine
    Yale School of MedicineClass of 1973
  • Yale College
    Yale CollegeB.A., 1969

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1975 - 2025
  • American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

  • Joseph B. Martin Dean's Leadership Award for Advancement of Women's Careers, Harvard Medical School, 2016
  • Distinguished Lecturer American Psychiatric Association, 2015
  • Outstanding Psychiatrist in Research Massachusetts Psychiatric Society, 2014
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Behavioral inhibition in childhood predicts smaller hippocampal volume in adolescent offspring of parents with panic disorder  
    Schwartz CE, Kunwar PS, Hirshfeld-Becker DR, Henin A, Vangel MG, Rauch SL, Biederman J, Rosenbaum JF, Transl Psychiatry, 1/1/2015
  • Pharmacological approaches to the challenge of treatment-resistant depression  
    Ionescu DF, Rosenbaum JF, Alpert JE, Dialogues Clin Neurosci, 1/1/2015
  • Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study  
    Castro VM, Roberson AM, McCoy TH, Wiste A, Cagan A, Smoller JW, Rosenbaum JF, Ostacher M, Perlis RH, Neuropsychopharmacol, 1/1/2015
  • Join now to see all

Books/Book Chapters

  • Comprehensive Clinical Psychiatry 
    Stern TA, Fava M, Wilens TE, Rosenbaum JFElsevier, New York, NYEdition 2nd,2015
  • Psychopharmacology and Neurotherapeutics 
    Stern TA, Fava M, Wilens TE, Rosenbaum JFElsevier, New York, NYEdition 1st,2015
  • Handbook of Psychiatric Drug Therapy 
    Labbate LA, Fava M, Rosenbaum JF, Arana GWLippincott Williams & Wilkins, Philadelphia, PAEdition 6th,2010
  • Join now to see all

Abstracts/Posters

  • Maintenance treatment of high relapse-prone patients
    Rosenbaum JF, Sixth World Congress of Biological Psychiatry, Nice, France, 1/1/1997
  • Low energy radio waves for the treatment of anxiety: A double-blind study
    Sachs GS, Pasche B, Lafer B, Barbault A, Baldassano CF, Rosenbaum JF, American Psychiatric Association 149th Annual Meeting, New York, NY, 1/1/1996
  • Time to remission of depression with acute fluoxetine treatment
    Rosenbaum JF, Fava M, Quitkin FM, Fawcett J, Amsterdam J, Reimherr FW, Beasley CM, NCDEU 34th Annual Meeting, Psychopharmacology Bulletin, Marco Island, FL, 1/1/1994
  • Join now to see all

Lectures

  • But we need the eggs: perspectives on what psychiatry has been, can do, and must become 
    Toronto, Canada - 1/18/2015
  • Challenges with mental health treatment for returning veterans in a specialized private outpatient clinic 
    Chicago, IL - 1/29/2014
  • Ethical dilemmas in psychiatric practice 
    New York, NY - 1/6/2014
  • Join now to see all

Other

  • Combined MGH and McLean Hospital Special Broadcast: Advances in Psychiatry and the Treatment of Depression 
    Rosenbaum JF, Massachusetts General Hospital – Psychiatry Academy, Primedia Healthcare
    Boston, MA - 1/7/2007
  • Current Controversies in Pharmacotherapy 
    Rosenbaum JF, Massachusetts General Hospital – Psychiatry Academy, Primedia Healthcare
    Dallas, TX - 1/28/2005
  • Handbook of Psychiatric Drug Therapy for PDA 
    Labbate LA, Rosenbaum JF, Arana GW, and Hyman SE, Lippincott Williams & Willkins
    1/1/2005
  • Join now to see all

Press Mentions

  • How Do Psychedelics Combat Anxiety and Depression? MGH Researchers Are Determined to Find Out
    How Do Psychedelics Combat Anxiety and Depression? MGH Researchers Are Determined to Find OutJuly 25th, 2022
  • The Cannabis & Psychedelic Long-Game: Don’t Do This
    The Cannabis & Psychedelic Long-Game: Don’t Do ThisAugust 13th, 2021
  • Back to the Future: Psychedelic Drugs in Psychiatry
    Back to the Future: Psychedelic Drugs in PsychiatryJune 22nd, 2021
  • Join now to see all

Grant Support

  • Children At Risk For Anxiety Disorders: A Follow UP StudyNational Institute Of Mental Health2007–2008
  • Family Imaging Study Of Children At Risk For AnxietyNational Institute Of Mental Health2006–2008
  • Children At Risk For Anxiety Disorders: A Follow UP Stu*National Institute Of Mental Health2005–2006
  • Children At Risk For Anxiety Disorders:A Follow UP StudyNational Institute Of Mental Health2004
  • A Longitudinal Follow UP Of Children At Risk For AnxietyNational Institute Of Mental Health2000–2003
  • Course Of Treatment Resistant DepressionNational Center For Research Resources2000–2002
  • Follow-Up Of Children At Risk For Anxiety DisordersNational Institute Of Mental Health1999
  • Psychopathology In Children Of Agoraphobic ParentsNational Institute Of Mental Health1993–1997
  • Adjuncts To Fluoxetine Treatment Of DepressionNational Institute Of Mental Health1994–1996
  • Adjuncts To Fluoxetine Trtmt Of Refractory DepressionNational Institute Of Mental Health1992–1993

Hospital Affiliations

Dr. Jerrold Rosenbaum, Dr. Jerrold Rosenbaum, MD, Dr. J Rosenbaum, Dr. Jerrold Frank Rosenbaum